Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Sold by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC reduced its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 9.0% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 16,780 shares of the biopharmaceutical company’s stock after selling 1,664 shares during the period. Mutual of America Capital Management LLC’s holdings in Catalyst Pharmaceuticals were worth $334,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the stock. Arizona State Retirement System boosted its stake in Catalyst Pharmaceuticals by 2.2% in the second quarter. Arizona State Retirement System now owns 29,733 shares of the biopharmaceutical company’s stock valued at $461,000 after acquiring an additional 654 shares during the period. GAMMA Investing LLC boosted its stake in Catalyst Pharmaceuticals by 62.1% in the third quarter. GAMMA Investing LLC now owns 1,778 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 681 shares during the period. XTX Topco Ltd boosted its stake in Catalyst Pharmaceuticals by 7.5% in the second quarter. XTX Topco Ltd now owns 11,134 shares of the biopharmaceutical company’s stock valued at $172,000 after acquiring an additional 773 shares during the period. Strategic Advocates LLC boosted its stake in Catalyst Pharmaceuticals by 6.5% in the second quarter. Strategic Advocates LLC now owns 14,142 shares of the biopharmaceutical company’s stock valued at $219,000 after acquiring an additional 864 shares during the period. Finally, Sei Investments Co. boosted its stake in Catalyst Pharmaceuticals by 1.3% in the second quarter. Sei Investments Co. now owns 84,458 shares of the biopharmaceutical company’s stock valued at $1,308,000 after acquiring an additional 1,098 shares during the period. 79.22% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on CPRX shares. Stephens assumed coverage on Catalyst Pharmaceuticals in a research note on Monday, November 18th. They issued an “overweight” rating and a $35.00 target price for the company. Citigroup boosted their price objective on Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. HC Wainwright reiterated a “buy” rating and set a $30.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Friday, November 8th. StockNews.com upgraded Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 9th. Finally, Truist Financial boosted their price objective on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a “buy” rating in a research report on Monday, November 11th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $31.14.

Catalyst Pharmaceuticals Price Performance

Shares of NASDAQ:CPRX opened at $22.34 on Friday. Catalyst Pharmaceuticals, Inc. has a 12 month low of $13.00 and a 12 month high of $24.27. The stock has a market cap of $2.66 billion, a price-to-earnings ratio of 18.93, a PEG ratio of 3.26 and a beta of 0.75. The stock’s 50 day moving average price is $21.21 and its 200 day moving average price is $18.69.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.